...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Management and Research >Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma
【24h】

Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma

机译：血小板计数，白蛋白和中性粒细胞淋巴细胞癌患者血小板复发性的预后价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Peripheral blood inflammation factor neutrophil-lymphocyte ratio (NLR), platelet count (PLT) and nutritional factor serum albumin (ALB) have been proposed as prognostic markers of head and neck squamous carcinoma cancer (HNSCC) in recent years. In the current study, nomogram predict models based on pre-treatment hematological parameters and a modified risk-stratified score system have been built. Methods: A total of 197 patients with oropharyngeal, hypopharyngeal and laryngeal cancers receiving multimodality treatment between 2012 and 2014 were included. The pre-treatment ALB, neutrophil, lymphocyte and platelet count (PLT) were detected. Cancer-specific survival and locoregional recurrence (LRC) by 5 years’ follow-up in the cases were obtained. To integrate clinical characteristics, we propose a modified risk-stratified score system. Kaplan–Meier method, proportional hazards COX model, logistic models were used to establish nomograms within external validation. Results: Five-year LRC was decreased (p=0.004) for 140 patients with pre-treatment NLR 2.77. Five-year LRC and 5-year cancer-specific survival were decreased (p=0.031, p=0.021) with pre-treatment PLT ≥ 248× 10sup9/sup/L. Comparison of univariate parametric models demonstrated that pre-treatment NLR evaluation and PLT 248× 10sup9/sup/L were better among tested models. On Bayesian information criteria (BIC) analysis, the optimal prognostic model was then used to develop nomograms predicting 3- and 5-year LRC. The external validation of this predictive model was confirmed in 57 patients from another hospital. Conclusion: Pre-treatment NLR elevation and PLT 248× 10sup9/sup/L are promising predictors of prognosis in patients with operable HNSCC. Nomograms based on the pre-treatment hematological markers and modified risk-stratified score system provide distinct risk stratifications. There results provided the feasibility of anti-inflammatory and antiplatelet treatments for HNSCC patients.
机译：背景：近年来，已经提出了近年来近年来头部和颈鳞状癌癌（HNSCC）的预后标志物的外周血炎症因子中性粒细胞淋巴细胞比（NLR），血小板计数（PLT）和营养因子血清白蛋白（ALB）。在目前的研究中，已经建立了基于前治疗前血液学参数和修改的风险分层评分系统的罗维图预测模型。方法：包括在2012年和2014年间接受多层疗法治疗的197例口咽，白阴性和喉癌患者。检测治疗前的ALB，中性粒细胞，淋巴细胞和血小板计数（PLT）。癌症特异性存活率和招生复发（LRC）在案件中的5年后续随访。为了整合临床特征，我们提出了一种修改的风险分层评分系统。 Kaplan-Meier方法，比例危险Cox模型，物流模型用于在外部验证中建立拓图。结果：140例预处理NLR <2.77的140名患者减少了五年的LRC（p = 0.004）。 5年LRC和5年的癌症特异性存活率（p = 0.031，p = 0.021），预处理PLT≥248×10 9 / l。单变量参数模型的比较证明，在测试模型中，预处理NLR评估和PLT> 248×10 9 / L在更好。关于贝叶斯信息标准（BIC）分析，随后使用最佳预后模型来开发预测3年和5年LRC的载体图。在另一医院的57名患者中确认了这种预测模型的外部验证。结论：预处理NLR升降和PLT> 248×10 9 / L是可操作HNSCC患者预后预测的预测因子。基于前治疗前血液学标志物和修改的风险分层评分系统提供了明显的风险分层的载体。结果提供了HNSCC患者的抗炎和抗血小板治疗的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号